Impact of Guideline-Directed Medical Therapy on 2-Year Mortality in Japanese Patients Undergoing Endovascular Therapy for Femoropopliteal Lesions - Results of the Multicenter GEMINI-FP Study.
{"title":"Impact of Guideline-Directed Medical Therapy on 2-Year Mortality in Japanese Patients Undergoing Endovascular Therapy for Femoropopliteal Lesions - Results of the Multicenter GEMINI-FP Study.","authors":"Tatsuro Takei, Takahiro Tokuda, Naoki Yoshioka, Kenji Ogata, Akiko Tanaka, Shunsuke Kojima, Kohei Yamaguchi, Takashi Yanagiuchi, Tatsuya Nakama","doi":"10.1253/circj.CJ-25-0086","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The effect of guideline-directed medical therapy (GDMT) on mid-term mortality in Asian patients, including Japanese patients, who have undergone endovascular therapy (EVT) for lower extremity artery disease remains still unclear. This study evaluated the effects of GDMT, defined as the combined prescription of antiplatelet agents, statins, and angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, on 2-year mortality in Japanese patients undergoing EVT for femoropopliteal (FP) lesions.</p><p><strong>Methods and results: </strong>In this multicenter retrospective study, 1,756 registered patients were divided into 2 groups: those who received all 3 medications that comprised GDMT (full GDMT group) and those who received ≤2 medications (non-GDMT group). After propensity score matching, the baseline characteristics did not differ significantly between the 413 pairs of participants in the full GDMT and non-GDMT groups. All-cause mortality within 2 years was significantly lower in the full GDMT than non-GDMT group (14.3% vs. 20.8%; log-rank P=0.030). Mortalities from cardiovascular and cardiocerebrovascular diseases within 2 years were also significantly lower in the GDMT group (4.2% vs. 9.5% [log-rank P=0.021] and 4.2% vs. 10.5% [log-rank P=0.007], respectively).</p><p><strong>Conclusions: </strong>In Japanese patients undergoing EVT for FP lesions, GDMT may improve all-cause, cardiovascular, and cardiocerebrovascular mortality within 2 years.</p>","PeriodicalId":50691,"journal":{"name":"Circulation Journal","volume":" ","pages":"638-646"},"PeriodicalIF":3.7000,"publicationDate":"2025-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Circulation Journal","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1253/circj.CJ-25-0086","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/3/28 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0
Abstract
Background: The effect of guideline-directed medical therapy (GDMT) on mid-term mortality in Asian patients, including Japanese patients, who have undergone endovascular therapy (EVT) for lower extremity artery disease remains still unclear. This study evaluated the effects of GDMT, defined as the combined prescription of antiplatelet agents, statins, and angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, on 2-year mortality in Japanese patients undergoing EVT for femoropopliteal (FP) lesions.
Methods and results: In this multicenter retrospective study, 1,756 registered patients were divided into 2 groups: those who received all 3 medications that comprised GDMT (full GDMT group) and those who received ≤2 medications (non-GDMT group). After propensity score matching, the baseline characteristics did not differ significantly between the 413 pairs of participants in the full GDMT and non-GDMT groups. All-cause mortality within 2 years was significantly lower in the full GDMT than non-GDMT group (14.3% vs. 20.8%; log-rank P=0.030). Mortalities from cardiovascular and cardiocerebrovascular diseases within 2 years were also significantly lower in the GDMT group (4.2% vs. 9.5% [log-rank P=0.021] and 4.2% vs. 10.5% [log-rank P=0.007], respectively).
Conclusions: In Japanese patients undergoing EVT for FP lesions, GDMT may improve all-cause, cardiovascular, and cardiocerebrovascular mortality within 2 years.
背景:指南导向药物治疗(GDMT)对亚洲患者(包括日本患者)接受血管内治疗(EVT)治疗下肢动脉疾病的中期死亡率的影响尚不清楚。本研究评估了GDMT(定义为抗血小板药物、他汀类药物、血管紧张素转换酶抑制剂或血管紧张素受体阻滞剂的联合处方)对日本因股腘动脉(FP)病变接受EVT的患者2年死亡率的影响。方法与结果:在这项多中心回顾性研究中,1756例注册患者被分为两组:全部接受含GDMT的3种药物治疗组(全GDMT组)和接受≤2种药物治疗组(非GDMT组)。在倾向评分匹配后,在完全GDMT组和非GDMT组的413对参与者之间,基线特征没有显着差异。完全GDMT组2年内全因死亡率显著低于非GDMT组(14.3% vs. 20.8%;log-rank P = 0.030)。GDMT组2年内心血管和心脑血管疾病的死亡率也显著降低(分别为4.2%对9.5% [log-rank P=0.021]和4.2%对10.5% [log-rank P=0.007])。结论:在日本因FP病变而接受EVT的患者中,GDMT可能在2年内改善全因死亡率、心血管死亡率和心脑血管死亡率。
期刊介绍:
Circulation publishes original research manuscripts, review articles, and other content related to cardiovascular health and disease, including observational studies, clinical trials, epidemiology, health services and outcomes studies, and advances in basic and translational research.